ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.